Literature DB >> 1261489

Effect of the ergot derivative lisuride hydrogen maleate on serum prolactin concentrations in female rats.

K J Gräf, F Neumann, R Horowski.   

Abstract

The influence of a new synthetic ergot derivative, lisuride hydrogen maleate (LHM) on serum prolactin (PRL) concentrations was investigated in female rats using different test models: 1. in reserpine (R)-pretreated intact females, and 2. in ovariectomized (OVX) estradiol benzoate (E2)-primed animals with or without an additional pretreatment with R. In all the models used LHM was strongly effective in lowering serum PRL. Doses from 0.025 to 0.5 mg/kg LHM, given orally as well as subcutaneously, suppressed serum PRL. Depending on the dose used, the serum PRL was lowered to a different extent for up to 12 h. LHM was at least as effective as the well-known potent inhibitor of PRL secretion CB-154 in lowering serum PRL in OVX rats primed with E2. The effects of R, E2, and LHM are described in relation to their mode of action within the hypothalamic-hypophyseal system which regulates PRL secretion. While the increase in serum PRL induced by R seems to be directly relatable to its known catecholamine depletion, the circadian rhythm of PRL secretion induced by E2 seems to be influenced or mediated by central neural mechanisms. The effects of LHM on serum PRL in these test models can be related to its dopaminergic action and constitute further evidence for the central functions of dopaminergic mechanisms in the regulation of PRL secretion.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1261489     DOI: 10.1210/endo-98-3-598

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  10 in total

Review 1.  Medical treatment of prolactinomas.

Authors:  Annamaria Colao; Silvia Savastano
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

Review 2.  A history of dopamine agonists. From the physiology and pharmacology of dopamine to therapies for prolactinomas and Parkinson's disease - a subjective view.

Authors:  R Horowski
Journal:  J Neural Transm (Vienna)       Date:  2006-08-10       Impact factor: 3.575

Review 3.  Classical dopamine agonists.

Authors:  R Horowski; P-A Löschmann
Journal:  J Neural Transm (Vienna)       Date:  2019-02-25       Impact factor: 3.575

4.  Hypothermic action of lisuride in rats and differences to bromocriptine in the antagonistic effect of neuroleptics.

Authors:  R Horowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-03       Impact factor: 3.000

Review 5.  Pharmacology of bromocriptine in health and disease.

Authors:  A E Mehta; G Tolis
Journal:  Drugs       Date:  1979-05       Impact factor: 9.546

6.  Pituitary secretion after administration of a new cerebroactive drug, fipexide.

Authors:  E Rolandi; R Franceschini; A Marabini; V Messina; P Bongera; T Barreca
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

7.  Comparative evaluation of lisuride and terguride, ergot alkaloid derivatives, on the field-stimulated vas deferens of mouse.

Authors:  M R Carratù; A DeSerio; D Mitolo-Chieppa; F Federico
Journal:  J Neural Transm Gen Sect       Date:  1991

8.  Dopaminergic modulation of adenylate cyclase stimulation by vasoactive intestinal peptide in anterior pituitary.

Authors:  P Onali; J P Schwartz; E Costa
Journal:  Proc Natl Acad Sci U S A       Date:  1981-10       Impact factor: 11.205

9.  Experimental studies of apocrine secretion in the dorsal prostate epithelium of the rat.

Authors:  G Aumüller; G Adler
Journal:  Cell Tissue Res       Date:  1979-04-30       Impact factor: 5.249

10.  Effects of lisuride on body temperature of rats and rabbits: relation to microsomal biotransformation and dopaminergic receptor stimulation.

Authors:  M O Carruba; S Ricciardi; J Negreanu; M Calogero; P Mantegazza
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.